Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study - PubMed
6 hours ago
- #real-world outcomes
- #follicular lymphoma
- #CAR-T therapy
- CAR-T therapy is a breakthrough for relapsed/refractory follicular lymphoma (FL).
- Real-world study compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in 136 patients (2021-2024).
- Axi-cel showed higher overall response rate (96% vs 80%) and complete response rate (88% vs 71%) than tisa-cel.
- Progression-free survival was longer with axi-cel (30.5 months vs 11.9 months).
- Overall survival did not significantly differ between the two therapies.
- Cytokine release syndrome (CRS) rates were similar (75% for both), but axi-cel had higher neurotoxicity (ICANS: 42% vs 17%).
- After statistical adjustment, efficacy was similar, but axi-cel retained higher toxicity.
- Real-world outcomes showed inferior progression-free survival compared to clinical trials.